<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00559299</url>
  </required_header>
  <id_info>
    <org_study_id>HTP110333</org_study_id>
    <nct_id>NCT00559299</nct_id>
  </id_info>
  <brief_title>Patient Tolerability Study of GSK163090</brief_title>
  <official_title>A Randomized, Single-blind, Placebo-controlled, 2 Part Study to Evaluate the Safety and Tolerability of GSK163090 at Single and Repeat Doses in Subjects With MDD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of a new drug,&#xD;
      GSK163090, which is being developed for the treatment of depression and anxiety disorders.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of GSK163090: Clinical laboratory, ECGs and vital signs assessments Questionnaire - DESS(Discontinuation Emergent Signs and symptoms)</measure>
    <time_frame>All over 10 days post dose for Group 1 and over 3 weeks for subjects in groups 2 and 3.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>•Questionnaires •Prolactin, cortisol •PK parameters for GSK163090</measure>
    <time_frame>All over 10 days post dose for Group 1 and over 3 weeks for subjects in groups 2 and 3.</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <condition>Major Depressive Disorder (MDD)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK163090</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects between the ages of 18 - 65 years with a psychiatric&#xD;
             diagnosis of a MDE associated with MDD according to DSM-IV-TR (296.2/296.3) whose&#xD;
             symptoms are considered mild to moderate and have not been taking antidepressant&#xD;
             medication at the time of screening and for at least 4 weeks prior to randomisation.&#xD;
&#xD;
          -  If female, the subject is eligible to enter and participate in this study if she is&#xD;
             not lactating and is of:&#xD;
&#xD;
               1. Non-childbearing potential (i.e., physiologically incapable of becoming pregnant,&#xD;
                  including any female who is post-menopausal [defined as one year without menses&#xD;
                  for women &gt;45 years of age]); is surgically sterile [via hysterectomy and/or&#xD;
                  removal of the ovaries] or,&#xD;
&#xD;
               2. Child-bearing potential, has a negative pregnancy test at both screen and&#xD;
                  baseline (prior to investigational product administration), and agrees to&#xD;
                  acceptable methods of contraception&#xD;
&#xD;
          -  Body weight ≥ 50 kg and body mass index (BMI) between 18.5 - 35.0 kg/m2 inclusive.&#xD;
&#xD;
          -  Capable of giving informed consent and can comply with the study requirements and&#xD;
             timetable.&#xD;
&#xD;
          -  Subjects have a HAM-D17 score &gt; 18 and &lt;25 at screening and baseline.&#xD;
&#xD;
          -  The subject must be able to read, comprehend and record information.&#xD;
&#xD;
          -  Non-smoker or light (&lt; 10 cigarettes per day) smoker.&#xD;
&#xD;
          -  Agree to abstain from alcohol for 24 hours prior to the start of dosing until&#xD;
             collection of the final pharmacokinetic sample.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects whose symptoms of the MDE are better accounted for by another diagnosis.&#xD;
&#xD;
          -  As a result of any of the medical interview, physical examination or screening&#xD;
             investigations the physician responsible considers the subject unfit for the study.&#xD;
&#xD;
          -  The subject has a history of a drug reaction or other allergy which in the opinion of&#xD;
             the physician responsible contraindicates their participation in the study.&#xD;
&#xD;
          -  The subject is currently participating or has participated in a clinical trial with a&#xD;
             new chemical entity or any investigational drug during the previous 2 months. In&#xD;
             addition, the subject has not participated in clinical trials with more than 3 new&#xD;
             chemical entities in the past 12 months.&#xD;
&#xD;
          -  The subject has a screening ECG with parameters outside ranges defined in the protocol&#xD;
&#xD;
          -  The subject has a pulse rate &lt;45 or &gt;100 bpm and/or a systolic blood pressure &gt;150&#xD;
             and/or &lt;90 and/or a diastolic blood pressure &gt;90 and &lt;50.&#xD;
&#xD;
          -  History of long QT syndrome (personal or family) or other cardiac conduction disorder,&#xD;
             or other clinically significant cardiac disease.&#xD;
&#xD;
          -  The subject has any liver function test (LFT) elevated &gt;1.5 times above the reference&#xD;
             range at pre-study screening that remain elevated with a repeat LFT.&#xD;
&#xD;
          -  Any other clinically significant laboratory abnormality.&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements (including St John'sWort) within 7 days (or 14 days if the drug is a&#xD;
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first&#xD;
             dose of study medication, unless in the opinion of the Investigator and sponsor the&#xD;
             medication will not interfere with the study procedures or compromise subject safety.&#xD;
&#xD;
          -  Use of monoamine oxidase inhibitors (MAOI) and linezolid (antibiotic) for 1 month&#xD;
             prior to first dose of study medication.&#xD;
&#xD;
          -  Abuse of alcohol defined as an average weekly intake of greater than 21 units for&#xD;
             males and 14 units for females or an average daily intake of greater than 3 units for&#xD;
             males and 2 units for females. 1 unit is equivalent to a half-pint (220mL) of beer or&#xD;
             1 (25ml) measure of spirits or 1 glass (125ml) of wine.&#xD;
&#xD;
          -  Consumption of grapefruit juice or grapefruit within 7 days prior to the first dose of&#xD;
             study medication until collection of the last PK sample.&#xD;
&#xD;
          -  The subject is unable to abstain from strenuous physical activity for 48 h prior to&#xD;
             screening and follow up and for 48 h prior to and 48 h after each treatment period.&#xD;
&#xD;
          -  Where participation in study would result in donation of blood in excess of 500 mL&#xD;
             within a 90 day period&#xD;
&#xD;
          -  An unwillingness of male subjects to abstain from, or use a condom during, sexual&#xD;
             intercourse with pregnant or lactating women from the time of the first dose of study&#xD;
             medication until 90 days following administration of the last dose of study medication&#xD;
&#xD;
          -  OR&#xD;
&#xD;
          -  An unwillingness of the male subject to use a condom/spermicide in addition to having&#xD;
             their female partner use another form of contraception such as an IUD, oral&#xD;
             contraceptives, injectable progesterone, subdermal implants or a tubal ligation if the&#xD;
             woman could become pregnant from the time of the first dose of study medication until&#xD;
             90 days following administration of the last dose of study medication.&#xD;
&#xD;
          -  Current or recent (within one year) gastrointestinal disease; a history of&#xD;
             malabsorption, esophageal reflux, irritable bowel syndrome; frequent (more than once a&#xD;
             week) occurrence of heartburn; or any surgical intervention (e.g., cholecystectomy)&#xD;
             which would be expected to influence the absorption of drugs.&#xD;
&#xD;
          -  Subjects who, in the investigator's judgement, pose a homicidal or serious suicidal&#xD;
             risk, have made a suicide attempt within 6 months preceding screening or who have ever&#xD;
             been homicidal.&#xD;
&#xD;
          -  The subject has a history of a clinically significant abnormality of the neurological&#xD;
             system (including dementia and other cognitive disorders or significant head injury)&#xD;
             or any history of seizure (excluding febrile seizure).&#xD;
&#xD;
          -  The subject has tested positive for hepatitis C antibody or hepatitis B surface&#xD;
             antigen.&#xD;
&#xD;
          -  The subject has tested positive for HIV.&#xD;
&#xD;
          -  The subject has a past history of drug abuse or dependence according to DSM-IV TR&#xD;
             criteria within the past 12 months or has tested positive for urine drugs of abuse at&#xD;
             pre-study screening.&#xD;
&#xD;
          -  The subject has any history of serotonin syndrome or in the investigator's judgement,&#xD;
             a history of clinical significant intolerance to SSRIs.&#xD;
&#xD;
          -  Subjects with a history of migraine headaches that respond to treatment with triptan&#xD;
             medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>November 14, 2007</study_first_submitted>
  <study_first_submitted_qc>November 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2007</study_first_posted>
  <last_update_submitted>March 15, 2012</last_update_submitted>
  <last_update_submitted_qc>March 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>163090</keyword>
  <keyword>placebo-controlled</keyword>
  <keyword>MDD</keyword>
  <keyword>Depression</keyword>
  <keyword>Tolerability</keyword>
  <keyword>MDE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

